Learning Tracks

Patient groups represent an important ally for the review and approval of generics. The cost and access benefits of generics are understood the most by those that take them, and patients offer a unique perspective when advocating for changes among policymakers. In this session, speakers will discuss best practices for supporting patient advocacy groups and helping to amplify patient voices to enact real change. Ultimately, this session will explore the role of patients in drug development and the tools that can be used to improve the patient perspective.

Moderator: Rachel Gartner Clark
Group Director, Corporate Pricing & Public Affairs, Real Chemistry

Panelists:

Gavin Clingham
Director of Public Policy, Alliance for Patient Access

Sarah Ibrahim, PhD
Associate Director for Global Regulatory Affairs, Immediate Office, OGD, CDER, FDA

Partha Roy, PhD
Director, OB, OGD, CDER, FDA

Andrew Spiegel, Esq.
Executive Director, Global Colon Cancer Association